Brief: OSE Immunotherapeutics End-December Net Loss Widens To 16.6 Million Euros

Ose Immunotherapeutics SA

26/03/2021 17:26

March 26 (Reuters) - OSE IMMUNOTHERAPEUTICS SA  OSE.PA :
    * POSITIVE TEDOPI® RESULTS FOR STEP-1 OF PHASE 3 IN
NON-SMALL CELL
LUNG CANCER POST CHECKPOINT INHIBITORS FAILURE
    * REPORTS 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS
UPDATE
    * FINANCIAL VISIBILITY EXTENDED TO Q2 2022 THROUGH €18.6
MILLION
EQUITY RAISE IN NOVEMBER 2020
    * END-DEC NET LOSS EUR 16.6 MILLION VERSUS LOSS EUR 4.7
MILLION
YEAR AGO
    * END-DEC OPERATING LOSS EUR 19.0 MILLION VERSUS LOSS EUR
1.5
MILLION YEAR AGO
    * AS OF DECEMBER 31, 2020, THE COMPANY’S AVAILABLE CASH
AMOUNTED
TO €29.4 MILLION
    * FINANCING ENABLE THE COMPANY TO SUPPORT CLINICAL
DEVELOPMENT AND
RESEARCH AND DEVELOPMENT COSTS FOR EARLIER STAGE PRODUCTS UNTIL
Q2 2022

Source text for Eikon:  ID: 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))